Corporate Banner
Satellite Banner
Biologics & Bioprocessing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

MRC Technology and IBP CAS Collaboration Yields Humanized Anti-CD146 Antibody

Published: Wednesday, March 20, 2013
Last Updated: Wednesday, March 20, 2013
Bookmark and Share
Antibody inhibits tumour angiogenesis, migration and invasion.

MRC Technology has announced that it has successfully humanized an anti-CD146 monoclonal antibody.

The project forms part of an on-going collaboration between MRC Technology and the Institute of Biophysics, Chinese Academy of Sciences (IBP CAS) to develop the antibody as a cancer therapeutic.

The cell adhesion molecule CD146 plays a critical role in tumour angiogenesis, an essential process for cancer development and metastasis.

Researchers in the lab of Prof Xiyun Yan at IBP CAS developed an anti-CD146 monoclonal antibody that dramatically inhibits tumour angiogenesis, migration and invasion.

Humanization of the antibody is an essential step in the development of anti-CD146 as a therapeutic.

Dave Tapolczay, MRC Technology’s CEO said: “The IBP CAS is one of the world’s leading academic research institutions and we are very pleased with the results of this collaboration. We are hopeful that the positive evaluation results for the humanized antibody will prove to be a significant milestone in cancer therapy and the fight against the disease.”

MRC Technology has humanized over 50 antibodies to date, including two marketed products, Tysabri (natalizumab) and Actemra (tocilizumab).

A further six are in clinical trials (including vedolizumab) and two more in preclinical studies.


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,500+ scientific posters on ePosters
  • More than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

MRC Technology Appoints Technology Transfer Director
Appointment of Andrew Farquharson as Director from 1 September.
Wednesday, July 08, 2015
MRC Technology, Peptinnovate Collaborate
This partnership has been formed to assess the therapeutic potential in bone diseases of Peptinnovate’s unique peptides derived from the bacterium Mycobacterium tuberculosis.
Wednesday, June 10, 2015
MRC Technology and NYU School of Medicine Collaborate
Collaboration will develop develop biologics for inflammatory bone disease.
Thursday, April 23, 2015
First Treatment Approved under EAMS Developed Using Antibody Humanization Expertise at UK’s MRC Technology
New breakthrough immunotherapy (pembrolizumab) launched in the UK for treatment of adults with advanced melanoma.
Wednesday, March 11, 2015
Breakthrough Melanoma Treatment, Keytruda, Developed
New immunotherapy launched in the US for treatment of adults with advanced melanoma, developed using antibody humanization expertise at UK’s MRC Technology.
Friday, September 05, 2014
MRC Technology Announces Humanization of Anti-Tau Monoclonal Antibody
Antibody inhibits Tau aggregation involved in the pathology of Alzheimer’s and other neurodegenerative diseases.
Tuesday, July 22, 2014
MRC Technology, Daiichi Sankyo form Drug Discovery Collaboration
Initiative brings together global expertise to streamline drug discovery.
Wednesday, May 14, 2014
UCB and UK’s MRC Technology Sign Exclusive License Agreement
UCB to develop an antibody-based therapy for the treatment of fibrotic disease.
Friday, February 14, 2014
Scientific News
Less May Be More in Slowing Cholera Epidemics
Mathematical model shows more cases may be prevented and more lives saved when using one dose of cholera vaccine instead of recommended two doses.
NIH Launches Human RSV Study
Study aims to understand infection in healthy adults to aid development of RSV medicines, vaccines.
Flu Remedies Help Combat E. coli Bacteria
Physiologists from the University of Zurich have now discovered why the intestinal bacterium Escherichia coli (E. coli) multiplies heavily and has an inflammatory effect.
'Fountain of Youth' Protein Points to Possible Human Health Benefit
Patients with higher blood levels of growth factor have lower risk of cardiovascular problems.
Lemon Juice and Human Norovirus
Citric acid may prevent the highly contagious norovirus from infecting humans, scientists discovered from the German Cancer Research Center.
Study Backs Flu Vaccinations for Elderly
Brown University researchers found vaccines well matched to the year’s flu strain significantly reduce deaths and hospitalizations compared to when the match is poor, suggesting that vaccination indeed makes a difference.
Inciting an Immune Attack on Cancer Cells
A new minimally invasive vaccine that combines cancer cells and immune-enhancing factors could be used clinically to launch a destructive attack on tumors.
Protein Found to Play a Key Role in Blocking Pathogen Survival
Calprotectin fends off microbial invaders by limiting access to iron, an important nutrient.
Major Advance Toward More Effective, Long-Lasting Flu Vaccine
Collaboration shows vaccine candidate can produce powerful ‘broadly neutralizing antibodies’ in animal models.
Immune System: Help for Killer Cells
A study from the University of Bonn may show the way to more effective vaccines.
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!